Phase 3 RCT in people with CF carrying rare non-F508del variants: elexacaftor/tezacaftor/ivacaftor vs placebo improved percent predicted FEV1 by 9.2 points at 24 weeks; 84% of 620 rare variants responded in vitro.
RCT
Castellani et al. Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study